Comparison · NCT00091949-5b0ec50b
Pioglitazone vs Placebo: Composite Outcome of Fatal or Non-fatal Stroke, Fatal or Non-fatal MI or Episode of Serious Congestive Heart Failure
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Pioglitazone vs Placebo: Composite Outcome of Fatal or Non-fatal Stroke, Fatal or Non-fatal MI or Episode of Serious Congestive Heart Failure. Trial comparisons, record NCT00091949-5b0ec50b. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT00091949-5b0ec50b
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.106 | 0.0933 | 0.121 | wilson | |
| Risk in group 2 | 0.129 | 0.114 | 0.144 | wilson | |
| Risk difference, group 1 minus group 2 | -0.0223 | -0.0426 | -0.00203 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 0.826 | 0.695 | 0.983 | log | |
| Odds ratio, group 1 over group 2 | 0.806 | 0.662 | 0.981 | log | |
| Number needed to treat, for one fewer participant with the outcome on Pioglitazone than on Placebo | 44.8 | 23.5 | 492 | from the risk difference interval |
Source ClinicalTrials.gov
Groups2
Group 2 names the comparator: placebo.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Pioglitazone | pioglitazone: a thiazolidinedione drug | 206 | 1,939 | OG000 |
| Group 2 | Placebo | placebo: an inactive substance | 249 | 1,937 | OG001 |
Source ClinicalTrials.gov
Outcome
- Type
- SECONDARY
- Title
- Composite Outcome of Fatal or Non-fatal Stroke, Fatal or Non-fatal MI or Episode of Serious Congestive Heart Failure
- Description
- Time frame
- 5 years
- Population
Source ClinicalTrials.gov
Trial
- Title
- Insulin Resistance Intervention After Stroke Trial
- NCT number
- NCT00091949
- Phases
- PHASE3
- Conditions
- Stroke, Myocardial Infarction, Diabetes
- Interventions
- pioglitazone, placebo
- Lead sponsor
- Yale University
- Results first posted
- 2016-10-28
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT00091949?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT00091949-5b0ec50b